Impower-022 Phase III safety and efficacy trial of once monthly Islatravir for HIV prevention among cisgender women
This is a large randomized, active-controlled clinical trial to determine safety and efficacy of a novel antiretroviral agent to prevent HIV infection in cisgender women. The trial is sponsored by Merck with leadership from Merck, ICRC and the Bill and Melinda Gates Foundation.
Countries
Active Dates
01/01/2021 to 12/31/2025
Faculty Involved
Organizations
Health Topics